RGDXQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RGDXQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Response Genetics's Operating Income for the three months ended in Mar. 2015 was $-3.64 Mil. Response Genetics's Interest Expense for the three months ended in Mar. 2015 was $-0.38 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Response Genetics's Interest Coverage or its related term are showing as below:
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Response Genetics's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Response Genetics Annual Data | |||||||||||||||||||||
Trend | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | |||||||||||
Interest Coverage | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Response Genetics Quarterly Data | ||||||||||||||||||||
Sep10 | Dec10 | Mar11 | Jun11 | Sep11 | Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Dec15 | |
Interest Coverage | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | N/A |
For the Diagnostics & Research subindustry, Response Genetics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Response Genetics's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
If Interest Expense is negative and Operating Income is positive, then
Interest Coverage | = | -1 | * | Operating Income | / | Interest Expense |
Else if Interest Expense is negative and Operating Income is negative, then
The company did not have earnings to cover the interest expense. |
Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then
The company had no debt (1). |
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Response Genetics's Interest Coverage for the fiscal year that ended in Dec. 2015 is calculated as
Here, for the fiscal year that ended in Dec. 2015, Response Genetics's Interest Expense was $-0.34 Mil. Its Operating Income was $-21.38 Mil. And its Long-Term Debt & Capital Lease Obligation was $4.92 Mil.
Response Genetics did not have earnings to cover the interest expense. |
Response Genetics's Interest Coverage for the quarter that ended in Mar. 2015 is calculated as
Here, for the three months ended in Mar. 2015, Response Genetics's Interest Expense was $-0.38 Mil. Its Operating Income was $-3.64 Mil. And its Long-Term Debt & Capital Lease Obligation was $10.84 Mil.
Response Genetics did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's Financial Strength is.
Response Genetics (OTCPK:RGDXQ) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Thank you for viewing the detailed overview of Response Genetics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.
Roberto Mignone | 10 percent owner | C/O BRIDGER MANAGEMENT, LLC., 90 PARK AVENUE, 40TH FL., NEW YORK NY 10016 |
Bridger Management Llc | 10 percent owner | 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016 |
Swiftcurrent Offshore Ltd | 10 percent owner | C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104 |
David Schreiber | director | 15 TROTTERS LANE, MONROE CT 06468 |
Sam Chawla | director | 1640 MARENGO STREET, 6TH FLOOR, LOS ANGELES CA 90033 |
Van Den Broek Richard | director | 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830 |
Kevin Roy Harris | officer: Vice President and CFO | 345 N MAPLE DRIVE, SUITE 120, BEVERLY HILLS CA 90210 |
Kirk K Calhoun | director | 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054 |
Michael Serruya | director | C/O RESPONSE GENETICS, INC., 1640 MARENGO ST., 6TH FLOOR, LOS ANGELES CA 90033 |
Thomas A Bologna | director, officer: Chief Executive Officer | 4390 US ROUTE ONE, PRINCETON NJ 08540 |
Marxe Austin W & Greenhouse David M | 10 percent owner | C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022 |
Partners Swiftcurrent | 10 percent owner | 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016 |
Bridger Capital Llc | 10 percent owner | 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016 |
Plc Glaxosmithkline | 10 percent owner | 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS |
Michael A Metzger | director | C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451 |
From GuruFocus
By gurufocus 10qk • 11-09-2010
By gurufocus • 05-15-2009
By gurufocus 10qk • 05-14-2010
By gurufocus 10qk • 11-16-2009
By gurufocus 10qk • 08-22-2009
By GuruFocus Research GuruFocus Editor • 12-14-2009
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.